Secretin and Autism Ranking:

Additional Information

The Cochrane Review of secretin and autism (Reichow et al, 2012) identified and evaluated a number of studies that we have not included in our evaluation. This is because the findings of those studies have not yet been published in English-language, peer-reviewed journals.

However, we know that the following two trials sponsored by the Repligen Corporation (and mentioned in the Cochrane Review) were terminated in 2004 because they were unsuccessful.

• The Repligen Corporation was running a study to evaluate the efficacy of secretin in pre-school autistic children.  Clinical Trials Gov Ref: NCT00036244.  For more details, please see “A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children with Autism.”
• The Repligen Corporation was running at study to examine the effects of synthetic human secretin in autistic children with gastrointestinal dysfunction. Clinical Trials Gov Ref: NCT00036231. For more details please see “A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children with Autism and Gastrointestinal Dysfunction”.

Related Additional Information

• Secretin

Updated

16 Jun 2022

Last Review

01 Dec 2018

Next Review

01 Aug 2024